Heat Production, Conservation, And Loss Mechanisms

Foundations and mechanisms

Thermal homeostasis: compartments, sensors and control

Human thermoregulation is a negative-feedback control system maintaining core temperature approximately 36.5–37.5°C, with a normal circadian variation of about 0.5–1.0°C. The body is conventionally modelled as a core compartment comprising the brain, thoracoabdominal viscera and richly perfused tissues, and a peripheral compartment comprising skin, subcutaneous tissues and limbs. Under anaesthesia this distinction is clinically critical because vasodilatation permits redistribution of heat from core to periphery, producing a typical initial core temperature fall of 0.5–1.5°C in the first hour.

Thermal input arises from peripheral thermoreceptors in skin, deep tissues and viscera, plus central thermoreceptors, particularly in the preoptic anterior hypothalamus and spinal cord. Cold receptors are predominantly Aδ fibres and warm receptors predominantly C fibres. The hypothalamus integrates afferent input and generates graded efferent responses. In the awake adult, the interthreshold range between sweating and vasoconstriction is narrow, approximately 0.2–0.4°C; volatile and intravenous anaesthetic agents widen this to 2–4°C, making patients effectively poikilothermic over a clinically important temperature range.

Heat balance and units

Core temperature reflects the balance between metabolic heat production and heat exchange with the environment:

Heat storage = metabolic heat production − external heat loss ± heat transfer

Heat is measured in joules; 1 kcal = 4.184 kJ. Basal metabolic rate in an adult is approximately 70–100 W or 1 kcal/kg/hour. During shivering, heat production may increase 2–5-fold, reaching approximately 250–500 W, at the cost of increased oxygen consumption, carbon dioxide production, myocardial work and catecholamine release. Conversely, general anaesthesia reduces metabolic rate by approximately 15–30%, depending on depth, agent and temperature.

Parameter	Typical value	Exam relevance
Normal core temperature	36.5–37.5°C	Site-dependent; oesophageal, pulmonary artery and tympanic membrane best reflect core temperature
Perioperative hypothermia	<36.0°C	Common guideline threshold for active warming and audit
Mild hypothermia	32–35°C	Shivering, vasoconstriction, impaired coagulation and drug metabolism
Moderate hypothermia	28–32°C	Arrhythmias, reduced conscious level, slowed metabolism
Severe hypothermia	<28°C	High risk of ventricular fibrillation, profound bradycardia and coma

Mechanisms of heat production

Heat production is primarily a consequence of oxidative metabolism. Major contributors include basal cellular metabolism, hepatic metabolism, skeletal muscle tone, brown adipose tissue thermogenesis and shivering. In adults, skeletal muscle becomes dominant during cold stress. Infants rely more heavily on non-shivering thermogenesis via brown adipose tissue, mediated by sympathetic noradrenergic stimulation and mitochondrial uncoupling protein-1.

• Basal metabolism: determined by lean body mass, thyroid status, age and catecholamine tone.
• Diet-induced thermogenesis: typically contributes about 5–10% of daily energy expenditure.
• Shivering thermogenesis: involuntary oscillatory skeletal muscle activity; markedly increases oxygen consumption and may be deleterious in coronary disease, respiratory failure and neurosurgical patients.
• Hormonal thermogenesis: thyroid hormone increases basal metabolic rate over hours to days; catecholamines act more rapidly via β-adrenergic pathways.

Heat conservation

Heat conservation is achieved mainly by reducing cutaneous heat transfer. Arteriovenous shunt vasoconstriction in fingers, toes, ears and nose is the most important autonomic response. In the awake adult, the vasoconstriction threshold is approximately 36.5°C, but anaesthetic drugs reduce this threshold in a dose-dependent manner. Behavioural responses—seeking warmth, clothing and posture—are normally the most effective thermoregulatory defences, but are abolished in anaesthetised, sedated or critically ill patients.

Counter-current heat exchange in limbs limits heat loss by allowing venous blood returning from the periphery to be warmed by adjacent arteries. Piloerection is physiologically minor in humans. Peripheral vasoconstriction may create a large core-to-peripheral temperature gradient, typically 2–4°C in a cool environment.

Mechanisms of heat loss

Mechanism	Physical principle	Approximate contribution in theatre	Clinical modifiers
Radiation	Infrared electromagnetic heat transfer proportional to absolute temperature difference to the fourth power	~40–60%	Exposed skin surface, cold walls, low ambient temperature
Convection	Heat transfer to moving air or fluid	~20–30%	Laminar flow, draughts, forced-air warming, open cavities
Conduction	Direct molecular heat transfer to contacting surfaces	Usually <5%	Cold operating table, irrigation fluids, wet drapes
Evaporation	Latent heat loss from vaporisation of water	~10–20%, higher in major open surgery	Skin preparation, exposed viscera, burns, sweating
Respiratory loss	Warming and humidifying inspired gases	~5–10%	High fresh gas flows, dry gases, minute ventilation

Evaporation is energetically significant: vaporisation of water consumes approximately 2.4 kJ/g at body temperature. Thus 100 ml of evaporated water may remove about 240 kJ of heat. Radiation follows the Stefan–Boltzmann relationship; clinically, heat loss is driven by exposed surface area and the temperature gradient between skin and environment. Operating theatre ambient temperatures below 21°C substantially increase risk of inadvertent hypothermia, particularly in infants, the elderly and patients undergoing long, open or neuraxial procedures.

Thermoregulation under anaesthesia

General anaesthesia impairs thermoregulation through three mechanisms: redistribution hypothermia from vasodilatation, reduced metabolic heat production, and increased interthreshold range. Volatile agents, propofol, opioids and neuraxial blockade all reduce vasoconstriction and shivering thresholds. Neuraxial anaesthesia additionally blocks afferent thermal input and efferent sympathetic vasoconstriction below the block; patients may feel warm despite progressive core cooling. The classic intraoperative hypothermia curve comprises an early redistribution phase, a slower linear phase due to heat loss exceeding production, and a plateau when vasoconstriction re-emerges at a lower core temperature.

Clinical assessment and investigations

Clinical presentation and bedside assessment

Thermal derangements should be assessed as disorders of measured core temperature plus the patient’s capacity for heat production, conservation and loss. In anaesthetic practice, clinically important hypothermia is usually defined as core temperature <36.0°C; fever is typically >38.0°C, hyperpyrexia >40.0–41.0°C, and heat stroke as core temperature usually >40.0°C with central nervous system dysfunction. Interpretation must account for site, device, perfusion and timing: peripheral temperature may underestimate or lag behind core temperature during vasoconstriction, forced-air warming, bypass, shock or regional anaesthesia.

Measurement site	Clinical interpretation	Limitations
Pulmonary artery	Reference standard for mixed venous/core temperature	Invasive; available only with PA catheter
Distal oesophagus	Reliable during general anaesthesia if probe in lower third	Incorrect placement gives airway or gastric artefact
Nasopharynx/tympanic membrane	Useful surrogate for brain temperature when correctly positioned	Ambient contamination, wax, poor technique
Bladder/rectum	Acceptable for trends, especially during long cases	Lag with rapid temperature change; bladder affected by urine flow
Skin/axillary/oral	Screening in awake patients	Poor precision during vasoconstriction, shock, warming or cooling

Current perioperative guidance, including NICE CG65, recommends temperature measurement before induction and then at least every 30 minutes intra-operatively in patients receiving general or neuraxial anaesthesia for procedures lasting >30 minutes, with active warming if temperature is <36.0°C or the patient is at risk. Elective anaesthesia should generally not proceed if preoperative temperature is <36.0°C unless warming is instituted and urgency justifies proceeding.

Differential diagnosis

Clinical classification is most useful when linked to mechanism: reduced heat production, impaired conservation, excessive environmental loss, or pathological heat generation. Examination should document mental state, shivering, sweating, skin perfusion, rigidity, autonomic instability, drug exposure, endocrine history, infection source and environmental exposure.

Syndrome	Typical clues	Discriminating features
Inadvertent perioperative hypothermia	GA, neuraxial block, exposure, cold fluids, long surgery	Redistribution fall of 1–1.5°C in first hour; vasoconstriction/shivering blunted by anaesthetics
Environmental hypothermia	Cold exposure, alcohol, trauma, immersion	Bradycardia, J waves, coagulopathy, acidosis; paradoxical undressing in severe cases
Sepsis	Fever or hypothermia, vasodilatation, shock, source	Lactate elevation, inflammatory markers; hypothermia in sepsis implies high mortality risk
Malignant hyperthermia	Volatile agent or suxamethonium exposure	Early unexplained rise in ETCO2, tachycardia, masseter/generalised rigidity, acidosis, hyperkalaemia; temperature rise is late
Serotonin syndrome	SSRI/SNRI/MAOI, tramadol, linezolid, MDMA	Clonus, hyperreflexia, agitation, diarrhoea; rapid onset
Neuroleptic malignant syndrome	Dopamine antagonist or withdrawal of dopaminergic therapy	Lead-pipe rigidity, bradykinesia, CK elevation; evolves over 1–3 days
Thyroid storm	Thyrotoxicosis, surgery, infection	Hyperthermia, tachyarrhythmia, heart failure, diarrhoea, delirium; use Burch-Wartofsky scoring

Staging and severity thresholds

Condition	Severity threshold	Clinical implications
Mild hypothermia	32–35°C	Shivering, tachycardia, impaired platelet function, increased blood loss and wound infection risk
Moderate hypothermia	28–32°C	Reduced consciousness, bradyarrhythmias, atrial fibrillation, decreased MAC and drug metabolism
Severe hypothermia	<28°C	Coma, ventricular arrhythmias, refractory shock; handle gently to avoid VF
Heat exhaustion	Usually <40°C	Volume depletion, weakness, preserved cognition; no end-organ CNS injury
Heat stroke	Usually >40°C plus encephalopathy	Medical emergency; coagulopathy, rhabdomyolysis, hepatic and renal injury

Investigations and interpretation

Initial investigations are directed by severity and context. In moderate/severe hypothermia or hyperthermia, obtain ABG/VBG with lactate, glucose, U&E, calcium, magnesium, phosphate, FBC, coagulation profile, LFTs, CK, troponin if indicated, urinalysis for myoglobin, ECG and continuous capnography if anaesthetised. In suspected sepsis obtain cultures before antibiotics if this does not delay treatment. In toxicological syndromes consider serum salicylate, paracetamol, ethanol, lithium and urine drug screen; in endocrine presentations check TSH/free T4, cortisol and ketones where appropriate.

Key interpretation points are exam-relevant. Hypothermia shifts the oxyhaemoglobin dissociation curve left, increases blood gas gas-solubility and produces uncorrected analyser values at 37°C; most clinical management uses alpha-stat interpretation except in selected deep hypothermic circulatory arrest strategies. Coagulation tests are performed at 37°C and may underestimate in vivo coagulopathy. Potassium is critical: hyperkalaemia in hypothermic cardiac arrest may imply cell lysis and poor prognosis, although no single absolute cut-off is universally accepted; many ECMO/ECLS protocols regard K⁺ >8–12 mmol/L as a relative marker of non-survivability depending on context.

In malignant hyperthermia, supportive evidence includes rapidly rising ETCO₂ despite increased minute ventilation, mixed metabolic/respiratory acidosis, K⁺ elevation, CK often >10,000 IU/L later, myoglobinuria and hyperthermia rising 1–2°C every 5 minutes in fulminant cases. Definitive susceptibility testing is by in vitro contracture testing of skeletal muscle with halothane/caffeine; genetic testing for pathogenic RYR1 or CACNA1S variants is specific but not fully sensitive.

Scoring systems can support but not replace clinical judgement. The Hunter serotonin toxicity criteria are highly specific when serotonergic exposure plus spontaneous clonus, inducible/ocular clonus with agitation or diaphoresis, tremor with hyperreflexia, or hypertonia with temperature >38°C and clonus is present. The Burch-Wartofsky score supports thyroid storm: scores >45 are highly suggestive, 25–44 support impending storm. For perioperative hypothermia, the actionable threshold remains pragmatic: core temperature <36.0°C mandates active warming and evaluation for blood loss, shock, endocrine failure, sepsis and excessive anaesthetic-mediated vasodilatation.

Management, pharmacology and procedures

Perioperative temperature management: prevention and treatment of inadvertent hypothermia

Perioperative hypothermia is usually defined as a core temperature <36.0°C. Under general anaesthesia, redistribution of heat from core to peripheral compartments accounts for an initial fall of approximately 1.0–1.5°C in the first hour, because anaesthetic-induced vasodilatation abolishes tonic thermoregulatory vasoconstriction. NICE guidance recommends temperature measurement before induction, then at least every 30 min intra-operatively, and active warming if core temperature is <36.0°C or if anaesthesia is expected to exceed 30 min.

Intervention	Mechanism	Key practical points
Forced-air warming	Reduces radiant and convective heat loss; provides cutaneous heat gain	Most effective routine method; apply pre-induction when possible. Avoid obstructing surgical access or laminar flow concerns, which are generally less clinically important than hypothermia prevention.
Resistive heating blankets	Conductive heat transfer	Useful where forced air is impractical; avoid pressure injury and burns, especially in vasoconstricted or poorly perfused tissue.
Warmed IV fluids/blood	Prevents infusion-related heat loss	Recommended when >500 ml crystalloid or any blood product is given. One litre of room-temperature crystalloid may reduce mean body temperature by approximately 0.25°C.
Warmed, humidified gases	Reduces respiratory evaporative heat loss	Modest effect in adults; more relevant in paediatrics, prolonged ventilation and open cavity surgery.
Ambient theatre temperature	Reduces radiant gradient	Increase to at least 21°C before induction for high-risk patients; neonates and burns patients may require higher temperatures.

Core temperature sites suitable for anaesthesia include distal oesophageal, nasopharyngeal, bladder and pulmonary artery measurements. Tympanic and temporal artery devices are less reliable intra-operatively. Hypothermia increases wound infection, coagulopathy, transfusion requirement, myocardial ischaemia, delayed drug metabolism and prolonged recovery. Shivering may increase oxygen consumption by 200–400%, carbon dioxide production and catecholamine release.

Pharmacological management of shivering and thermoregulatory thresholds

Volatile agents, propofol and opioids impair autonomic thermoregulation in a dose-dependent, approximately linear fashion by widening the interthreshold range from around 0.2–0.4°C to several degrees Celsius. Treatment of postoperative shivering should combine active warming with drugs that lower the shivering threshold.

Drug	Typical adult dose	Mechanism and cautions
Meperidine/pethidine	12.5–25 mg IV	κ-opioid and α2-adrenergic effects; disproportionately reduces shivering threshold. Avoid repeated dosing in renal failure because norpethidine accumulates and may cause seizures.
Clonidine	0.5–1 microgram kg−1 IV slowly	α2-agonist reducing central sympathetic outflow; may cause bradycardia and hypotension.
Dexmedetomidine	0.2–0.7 microgram kg−1 h−1 infusion	α2-agonist; useful where sedation is acceptable. Context-sensitive half-time increases with prolonged infusion.
Tramadol	0.5–1 mg kg−1 IV	μ-opioid and monoaminergic effects; nausea, serotonin toxicity risk, lowers seizure threshold.
Magnesium sulphate	30–50 mg kg−1 IV load, then 10–15 mg kg−1 h−1	NMDA antagonism and reduced neuromuscular excitability; monitor reflexes, respiratory depression and potentiation of neuromuscular blockade.

Management of malignant hyperthermia and hypermetabolic crises

Malignant hyperthermia is a pharmacogenetic disorder, usually involving RYR1 or CACNA1S, triggered by volatile anaesthetics and suxamethonium. Early signs are unexplained rise in end-tidal CO₂, tachycardia, masseter rigidity, acidosis and hyperkalaemia; temperature rise is often late. Management is time-critical and should follow Association of Anaesthetists/MHAUS-style algorithms.

1. Stop triggers immediately; call for help and MH trolley; switch to 100% oxygen at high fresh gas flow, hyperventilate to reduce PaCO₂.
2. Administer dantrolene 2.5 mg kg⁻¹ IV, repeating every 5–10 min until clinical control; cumulative doses >10 mg kg⁻¹ may be required. Continue 1 mg kg⁻¹ every 4–6 h or infusion 0.25 mg kg⁻¹ h⁻¹ for at least 24 h because recrudescence occurs in approximately 20%.
3. Treat hyperkalaemia: calcium chloride 10 ml of 10% IV or calcium gluconate 30 ml of 10%, insulin 10 units soluble with 25 g glucose, bicarbonate if severe acidosis, and salbutamol as adjunct. Avoid calcium-channel blockers with dantrolene due to risk of hyperkalaemia and cardiovascular collapse.
4. Active cooling if core temperature >38.5–39°C: cold IV saline, surface cooling, lavage where appropriate; stop cooling at approximately 38°C to avoid overshoot hypothermia.
5. Monitor CK, potassium, ABG, lactate, coagulation, urine output and myoglobinuria; target urine output >2 ml kg⁻¹ h⁻¹, using crystalloid and diuretics if required.

Dantrolene acts at skeletal muscle ryanodine receptors to reduce calcium release from the sarcoplasmic reticulum. Each 20 mg vial of conventional dantrolene requires reconstitution with 60 ml sterile water; newer concentrated formulations reduce preparation time. Survivors require ICU monitoring, counselling, trigger-free future anaesthesia and referral for diagnostic testing, including caffeine-halothane contracture testing or genetic evaluation.

Hyperthermia, fever and heat illness

Fever is a regulated upward shift in hypothalamic set-point mediated by prostaglandin E₂; hyperthermia is unregulated heat accumulation and does not reliably respond to antipyretics. Paracetamol 1 g orally/IV every 6 h, maximum 4 g day⁻¹ in adults, is appropriate for symptomatic fever but not definitive therapy for heat stroke, MH, serotonin syndrome or neuroleptic malignant syndrome. NSAIDs reduce prostaglandin synthesis but may worsen renal injury, platelet dysfunction or gastrointestinal bleeding.

Heat stroke requires immediate cooling: evaporative cooling with tepid water and fans, ice packs to groin/axillae/neck, or cold-water immersion when feasible. Aim to reduce core temperature to <39°C within 30 min. Complications include rhabdomyolysis, DIC, hepatic injury, AKI, ARDS and cerebral oedema; follow-up should include renal, hepatic and neurological assessment before return to exertion.

Therapeutic hypothermia and targeted temperature management

Targeted temperature management after cardiac arrest has evolved from fixed hypothermia to active fever prevention. The TTM trial compared 33°C with 36°C after out-of-hospital cardiac arrest and found no mortality advantage; TTM2 found no benefit of 33°C over normothermia with fever prevention. Current practice is active temperature control, typically ≤37.5–37.8°C for at least 24 h in comatose survivors, with avoidance of pyrexia for 72 h. Cooling techniques include surface gel pads, intravascular catheters and cold fluids, but rapid large-volume cold saline prehospital is discouraged because of pulmonary oedema and rearrest risk. Rewarming should be controlled, commonly 0.25–0.5°C h⁻¹, to avoid vasodilatation, hypotension, electrolyte shifts and rebound hyperthermia.

Exam controversies and advanced synthesis

Perioperative hypothermia: guideline thresholds and the physiology behind them

For examination purposes, the key synthesis is that most intra-operative hypothermia is not due to excessive environmental loss alone, but to anaesthetic impairment of autonomic thermoregulation plus redistribution. General anaesthesia widens the interthreshold range from approximately 0.2–0.4°C in health to around 2–4°C, abolishes behavioural responses, reduces vasoconstrictor tone, and permits core-to-peripheral redistribution during the first hour. Neuraxial anaesthesia additionally blocks afferent thermal input and efferent vasoconstriction below the block, producing a deceptively warm periphery with falling core temperature.

The usual perioperative definition of inadvertent hypothermia is core temperature <36.0°C. NICE guidance recommends temperature measurement before induction, then at least every 30 minutes in patients receiving general or regional anaesthesia for procedures lasting >30 minutes, and active warming if temperature is <36°C or the case is expected to exceed 30 minutes. Patients should not normally be transferred from recovery to the ward until temperature is ≥36.0°C, unless active warming and monitoring continue.

Intervention	Physiological target	Exam-relevant limitations
Forced-air warming	Reduces cutaneous heat loss and supplies convective heat	Most effective routine method; efficacy reduced if applied late after redistribution has occurred
Pre-warming for 20–30 min	Increases peripheral heat content; reduces core-to-peripheral redistribution	Particularly valuable before neuraxial or combined anaesthesia
Warmed IV fluids	Prevents conductive heat loss from cold infusate	Important for large volumes; 1 L room-temperature crystalloid may reduce mean body temperature by about 0.25°C
Ambient temperature >21°C	Reduces radiation and convection gradient	Most relevant in children, burns, trauma and exposed cavities

Evidence, outcomes and controversies

The landmark trial by Kurz et al. demonstrated that maintaining normothermia in colorectal surgery reduced surgical wound infection and shortened hospital stay; another key trial showed reduced morbid cardiac events in high-risk patients. Hypothermia also increases blood loss and transfusion requirement through platelet dysfunction, impaired thrombin generation and fibrinolysis; a reduction of only 1–2°C is clinically relevant. Drug effects are prolonged: hypothermia reduces hepatic metabolism and renal clearance, increases volatile anaesthetic solubility, and prolongs neuromuscular blockade. A viva trap is to state that hypothermia simply “slows enzymes”; the better answer links reduced clearance, altered receptor kinetics, decreased minimum alveolar concentration by approximately 5% per °C, and delayed recovery.

A recurrent controversy is whether forced-air warming increases surgical site infection by disturbing laminar airflow. The prevailing interpretation of clinical evidence and guideline practice is that maintenance of normothermia is beneficial, and infection concerns have not displaced forced-air warming as standard care. Candidates should avoid overstating either side: the physical plausibility of airflow disruption exists, but patient-centred outcome data support active warming.

Temperature measurement: site selection and pitfalls

Core temperature is best estimated by pulmonary artery blood temperature, distal oesophageal temperature during general anaesthesia, nasopharyngeal temperature when correctly positioned, or bladder temperature when urine flow is adequate. Tympanic infrared devices are convenient but operator-dependent; skin and axillary measurements are poor during anaesthesia because vasoconstriction and warming devices alter gradients. During rapid thermal flux—induction, rewarming, cardiopulmonary bypass—measurement lag is a major source of error. In examinations, distinguish core temperature from mean body temperature, which includes a large peripheral compartment and better predicts redistribution.

Therapeutic hypothermia, fever control and hyperthermic syndromes

Post-cardiac arrest temperature management has evolved. Early trials favoured cooling to 32–34°C, but more recent TTM and TTM2 data support active prevention of fever with controlled temperature targets rather than routine deep hypothermia for all patients. A defensible exam answer is that comatose survivors of cardiac arrest require active temperature control, avoidance of fever, sedation to suppress shivering, and protocolised rewarming; local policy determines whether the target is 33°C or controlled normothermia, commonly ≤37.5–37.8°C.

Shivering is metabolically expensive, increasing oxygen consumption by up to 200–400%. It is treated by warming and pharmacological reduction of the shivering threshold. Meperidine is classically effective at 12.5–25 mg IV, partly via κ-opioid and α₂-mechanisms; clonidine 1–2 micrograms/kg IV and dexmedetomidine 0.2–0.7 micrograms/kg/h reduce shivering but may cause bradycardia and hypotension. Magnesium sulphate, tramadol and ketamine are alternatives in selected settings.

Condition	Key thermal physiology	Immediate management emphasis
Malignant hyperthermia	Uncontrolled skeletal muscle calcium release; heat production follows hypermetabolism	Stop triggers, 100% oxygen, dantrolene 2.5 mg/kg IV repeated until controlled; active cooling; treat hyperkalaemia/acidosis
Sepsis/fever	Raised hypothalamic set-point via PGE2	Treat cause; antipyresis for comfort/physiological stress, not simply to normalise a number
Heat stroke	Failure of heat dissipation; set-point not raised	Rapid cooling; evaporative or cold-water immersion depending context
Thyroid storm/NMS/serotonin syndrome	Increased heat production with impaired dissipation variably	Syndrome-specific therapy plus aggressive supportive cooling

Viva integration: common traps

• Radiation dominates awake heat loss in a cool operating theatre, but redistribution dominates early anaesthetic hypothermia.
• Sweating and vasodilatation are heat-loss mechanisms; shivering, non-shivering thermogenesis and vasoconstriction defend against cold.
• Heat loss from open cavities and wet skin is disproportionately evaporative; latent heat of vaporisation of water is approximately 2.43 kJ/g at body temperature.
• Children cool rapidly because of high surface-area-to-mass ratio, low insulation and limited behavioural compensation; neonates rely heavily on brown-fat non-shivering thermogenesis.
• Do not confuse fever with hyperthermia: fever is a regulated rise in set-point; heat stroke and malignant hyperthermia are failures of balance despite an unchanged or overwhelmed set-point.